Compare · NVO vs UPB
NVO vs UPB
Side-by-side comparison of Novo Nordisk A/S (NVO) and Upstream Bio Inc. (UPB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and UPB operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 547.9x UPB ($393.3M).
- NVO has been more active in the news (9 items in the past 4 weeks vs 4 for UPB).
- NVO has more recent analyst coverage (25 ratings vs 10 for UPB).
- Company
- Novo Nordisk A/S
- Upstream Bio Inc.
- Price
- -
- -
- Market cap
- $215.46B
- $393.3M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2024
- News (4w)
- 9
- 4
- Recent ratings
- 25
- 10
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest UPB
- Amendment: SEC Form SCHEDULE 13G/A filed by Upstream Bio Inc.
- SEC Form 10-Q filed by Upstream Bio Inc.
- Upstream Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress
- SEC Form SCHEDULE 13G filed by Upstream Bio Inc.
- Chief Business Officer Houghton Adam sold $4,270 worth of shares (700 units at $6.10), decreasing direct ownership by 3% to 23,601 units (SEC Form 4) (for withholding tax)
- CFO and COO Gray Michael sold $5,203 worth of shares (853 units at $6.10), decreasing direct ownership by 3% to 28,795 units (SEC Form 4) to satisfy withholding obligation
- Chief Executive Officer Sutherland Everett Rand sold $12,780 worth of shares (2,095 units at $6.10), decreasing direct ownership by 3% to 70,812 units (SEC Form 4) to satisfy withholding obligation
- Chief Medical Officer Deykin Aaron sold $5,460 worth of shares (895 units at $6.10), decreasing direct ownership by 3% to 33,197 units (SEC Form 4) (for withholding tax)
- General Counsel Ambrose Allison sold $2,910 worth of shares (477 units at $6.10), decreasing direct ownership by 3% to 16,048 units (SEC Form 4) to satisfy withholding tax